Journal Article Research Support, Non-U.S. Gov't Ppublish 7 citations
PubMed: 37706688 DOI: 10.1128/jvi.00724-23
Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants.
J Virol 97(10):e0072423
Authors: Man Xing, Yihan Wang, Xinyu Wang, Jiaojiao Liu, Weiqian Dai, Gaowei Hu, Furong He, Qian Zhao, Ying Li, Lingjin Sun, Yuyan Wang, Shujuan Du, Zhongwei Dong, Chongjie Pang, Zhidong Hu, Xiaoyan Zhang, Jianqing Xu, Qiliang Cai, Dongming Zhou
Affiliations
- Shanghai Public Health Clinical Center, Fudan University , Shanghai, China. Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University , Tianjin, China.
- Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University , Tianjin, China.
- MOE&NHC&CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infections Disease and Biosecurity, Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University , Shanghai, China.
- MOE&NHC&CAMS Key Laboratory of Medical Molecular, Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University , Shanghai, China.
- Department of Infectious Diseases, Tianjin Medical University General Hospital , Tianjin, China.
- Department of Clinical Laboratory, Tianjin Medical University General Hospital , Tianjin, China.
- Shanghai Public Health Clinical Center, Fudan University , Shanghai, China.
Abstract
The development of broad-spectrum SARS-CoV-2 vaccines will reduce the global economic and public health stress from the COVID-19 pandemic. The use of conserved T-cell epitopes in combination with spike antigen that induce humoral and cellular immune responses simultaneously may be a promising strategy to further enhance the broad spectrum of COVID-19 vaccine candidates. Moreover, this research suggests that the combined vaccination strategies have the ability to induce both effective systemic and mucosal immunity, which may represent promising strategies for maximizing the protective efficacy of respiratory virus vaccines.
MeSH
Cells, Sars-Cov-2, Immunization, Vaccines, Covid-19 Vaccines, Immunity, Mucosal, Viruses, Immunity, Severe Acute Respiratory Syndrome-Related Coronavirus
Cited by
- Next-Generation Adenoviral Vector-Based Vaccines for Severe Acute Respiratory Syndrome Coronavirus-2. Vaccines (Basel), 2025
- Pre-clinical studies of Schistosoma mansoni vaccines: A scoping review. PLoS Negl Trop Dis, 2025
- An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza. NPJ Vaccines, 2024
- Improved mRNA-based RSV vaccine with PreF forming enveloped virus-like particles. NPJ Vaccines, 2025
- B and T Cell Bi-Cistronic Multiepitopic Vaccine Induces Broad Immunogenicity and Provides Protection Against SARS-CoV-2. Vaccines (Basel), 2024
- T-Cell Epitope-Based Vaccines: A Promising Strategy for Prevention of Infectious Diseases. Vaccines (Basel), 2024